NLRP3 and cardiovascular disorder: For instance, Kim et al. [27] reported that β-hydroxybutyrate (BHB) modulated NLRP3 inflammasome activity in diabetes with the cardiovascular disease while Goldberg et al. [28] demonstrated that β-hydroxybutyrate (BHB) deactivates neutrophil NLRP3 inflammasome to relieve gout flares [27, 28].